Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation declines year over year

Q3 FY2026 stock-based compensation of $11.83M fell 0.6% year over year, ahead of the -42.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -9.8% a year.

Context

  • Stock-based compensation amounted to 23.4% of revenue in FY2025, down 43.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -0.6% holds above the trailing-twelve-month pace of -42.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$11.83M+0.9% QoQ
Last fiscal yearDec 2025
$61.58M-43.8% YoY
LTMSep 2026
$46.65M-42.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.6%——
1 year-43.8%——
3-year CAGR-9.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
61.58M USD
Year-over-year change
-43.8%
4-year CAGR
-3.1%

Stock-Based Compensation vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.2% is the 6th highest of 9, against a peer median of -10.3%.
  • Stock-based compensation amounts to 12.3% of revenue for IOVA, versus a peer median of 7.3%.
IOVA Competitors
Stock-Based Compensation for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
IMNMImmunome, Inc.LTM Sep 2026$37.41M USD+60.8%+68.9%—
IBRXImmunityBio, Inc.LTM Sep 2026$34.15M USD-8.0%-2.9%18.7%
REPLReplimune Group, Inc.LTM Dec 2025$32.43M USD-6.5%+13.1%—
IMCRImmunocore Holdings plcLTM Mar 2026$28.21M USD+14.1%—7.3%
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M USD-43.3%-31.8%340.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$9.87M USD-60.9%-19.2%—
LEGNLegend Biotech CorporationLTM Sep 2026$7.7M USD-87.8%—0.6%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
Peer median (excluding IOVA) —-10.3%-0.1%7.3%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
Deferred Income Tax00(3.48M)(2.83M)(2.07M)
Stock-Based Compensation69.77M84.02M62.63M109.63M61.58M
Change in Working Capital24.55M(2.89M)(6.52M)(122.56M)(24.27M)
Accounts Receivables00(149K)(69.19M)(13.11M)
Inventory00(10.12M)(39.92M)(14.21M)
Accounts Payables6.98M5.88M4.83M(7.84M)(6.66M)
Other Working Capital17.58M(8.78M)(1.08M)(5.61M)9.71M
Other Non-Cash Items6.01M871K(3.54M)(8.65M)6.01M
Operating Cash Flow(227.94M)(292.76M)(361.82M)(352.98M)(302.41M)
Capital Expenditures(37.57M)(20.43M)(22.29M)(11.07M)(33.84M)
Acquisitions (Net)(37.71M)(276.88M)(212.63M)(52.57M)0
Purchases of Investments(725.21M)(245.82M)(205.9M)(460.77M)(318.67M)
Sales of Investments762.91M522.7M285.58M428M400M
Other Investing Activities37.71M276.88M000
Investing Cash Flow132K256.46M(155.24M)(96.41M)47.5M
Debt Repayment1M0000
Common Stock Issued203.16M189.5M463.28M397.3M306.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities35.11M648K(322K)(6.64M)(7.06M)
Financing Cash Flow239.27M190.15M462.96M390.66M300.77M
Effect of Forex Changes00(2.74M)(541K)1.52M
Net Change in Cash11.46M153.85M(56.84M)(59.27M)47.38M
Free Cash Flow(265.52M)(313.18M)(384.11M)(364.05M)(336.24M)

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.